-
Company Profile
MTG Co Ltd – Company Profile
MTG Co Ltd (MTG) is a manufacturer and seller of beauty and fitness products. The company’s product portfolio includes beauty care products, fitness products, protein shake, beauty devices and facial exercise equipment. MTG markets its products through brand stores, department stores, specialty stores, travel retail outlets and e-commerce sites. It offers products under various brand names, including ReFa, SIXPAD, MDNA Skin Style, Plosion, PAO, Inbeaute, Taikans Stream, ON&DO, With Mask, e-3X, Megly, Do Kirei, New Peace, and CAXA UP. The...
Add to Basket -
Sector Analysis
Esports Market Size, Share, Trends and Analysis by Region, Revenue Stream, Gaming Genre and Segment Forecast to 2030
Esports Market Overview The Esports market size by revenue will be valued at $1.64 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 16.7% over the forecast period. The adoption of Esports will be supported by increasing adoption of mobile and PC gaming, high accessibility and inclusiveness, and the development of the mobile 5G connectivity. Esports is moving from local area network (LAN)-based wired connectivity to 5G-powered wireless connections. Over the next two...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Track & Monitor
Gene Therapy Market Opportunity For CMOs – 2019 PharmSource Edition
This report will explore whether the bio/pharma industry is adequately prepared for future gene therapy developments and whether CDMOs are making appropriate investments in the capacity and technology to support the coming opportunity.